| Autor: |
Hartikainen AK; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Khan I; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Karjalainen EK; Department of Gastrointestinal Surgery, Helsinki University Hospital, Helsinki, Finland., Renkonen-Sinisalo L; Department of Gastrointestinal Surgery, Helsinki University Hospital, Helsinki, Finland.; Genome-Scale Biology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arkkila P; Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.; Department of Medicine, University of Helsinki, Helsinki, Finland., Jalanka J; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lepistö AH; Department of Gastrointestinal Surgery, Helsinki University Hospital, Helsinki, Finland.; Genome-Scale Biology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Satokari R; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. |
| Abstrakt: |
Altered microbiota and impaired host immune function have been linked to the pathogenesis of pouchitis. We used 16S rRNA gene sequencing and RNA sequencing data from a previous randomized clinical trial (RCT) on fecal microbiota transplantation (FMT) therapy in 26 chronic pouchitis patients with one-year follow-up. We analyzed changes in both luminal and mucosal microbiota composition, as well as in host mucosal gene expression to gain insights into the host-microbiota interactions possibly underlying clinical outcomes of the patients. Antibiotic type and pattern of use were significant drivers of the luminal microbiota at baseline. Differential gene expression analysis indicated transition from ileal to colonic gene expression in the pouch, and upregulation in inflammation- and immune system-related pathways in the pouch. At 4 weeks, the non-relapsed FMT patients had a lower microbiota dissimilarity to the donor than the non-relapsed placebo patients ( p = .02). While two FMT-treated patients showed a shift toward the donor's microbiota during the one-year follow-up, the overall FMT microbiota modulation effect was low. Patient's luminal and mucosal microbiota profiles were unstable in both FMT and placebo groups. Expression of the chemokine receptor CXCR4 was downregulated at 52 weeks compared to the baseline in the non-relapsed patients in both FMT and placebo groups. Microbiota modulation by FMT seems to be low in this patient group. The microbiota composition or alterations did not explain the relapse status of the patients. Some evidence for remission-related host gene expression pattern was found; specifically, CXCR4 expression may have a role in sustained remission. |
